NVO
Novo Nordisk A/S · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -5.0% ·
share flow -2.8% ·
net new positions -5.3%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 347.39K | $13.21M | n/a | −1 |
| Q2 2026 | 132 | 0 | 235.88M | $11.31B | +12 | −13 |
| Q1 2026 | 134 | -8 | 242.80M | $8.91B | +5 | −13 |
| Q4 2025 | 140 | +1 | 228.46M | $11.63B | +3 | −2 |
| Q3 2025 | 19 | -1 | 80.89M | $4.49B | +2 | −3 |
| Q2 2025 | 17 | -1 | 53.30M | $3.68B | +1 | −2 |
| Q1 2025 | 16 | 0 | 43.10M | $3.00B | n/a | n/a |
| Q4 2024 | 16 | -1 | 48.20M | $4.15B | +1 | −2 |
| Q3 2024 | 16 | -1 | 43.13M | $5.09B | +1 | −2 |
| Q2 2024 | 17 | n/a | 46.04M | $6.57B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 14.08M | +1.0% | $781.04M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | Morgan Stanley ✦ | 12.41M | n/a | $688.82M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 3 | JPMorgan Chase ✦ | 10.82M | n/a | $600.22M | 0.0% | n/c | 1 | SEC ↗ ×32 |
| 4 | Fisher Asset Management ✦ | 10.32M | -6.2% | $572.82M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 5 | Goldman Sachs Group ✦ | 6.72M | n/a | $372.69M | 0.1% | n/c | 1 | SEC ↗ ×3 |
| 6 | State Street Global Advisors ✦ (passive) | 6.11M | +1.0% | $340.12M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 4.85M | -21.8% | $269.24M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 3.96M | -9.1% | $219.95M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 9 | Citadel Advisors ✦ | 3.13M | +690.0% | $173.80M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 2.88M | -41.6% | $159.92M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 11 | Markel Group ✦ | 2.37M | +4.9% | $131.44M | 1.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 1.69M | -23.7% | $93.86M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 1.05M | New | $58.24M | 0.1% | New | 1 | SEC ↗ |
| 14 | Capital World Investors ✦ | 210.86K | -2.2% | $11.70M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 138.95K | New | $7.71M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 123.80K | -1.3% | $6.87M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 17 | Millennium Management ✦ | 23.90K | -33.0% | $1.33M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 4.14K | -8.8% | $229,951 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Baillie Gifford ✦ | 314 | +141.5% | $17,424 | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $58.24M | 0.1% |
| Bridgewater Associates | $7.71M | 0.0% |
Exited
| Tiger Global Management | $87.59M | was 0.3% |
| Wellington Management | $17.99M | was 0.0% |
| Marshall Wace | $2.15M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 1.21M shares, $43.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.